Drug intelligence / Profile preview

CAR-iNK 006

Development stage: Preclinical
Lead developer: ThinkingBiomed
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CAR-iNK 006 is an induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy under development by ThinkingBiomed. The candidate is engineered to express a CAR that recognizes tumor-associated antigens, enabling the NK cells to mediate cytotoxic killing of malignant cells. As an iPSC-derived product, it is designed to provide an "off-the-shelf" therapeutic option, potentially overcoming the limitations of patient-specific autologous therapies. It is currently in the early research/preclinical stage for the treatment of various cancers, including lung cancer, liver cancer, colorectal cancer, and B-cell lymphoma.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on CAR-iNK 006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-iNK 006.

Explore the full profile